Investor Overview

Corporate Profile
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Company’s NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The Company’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on the Company’s NAV Technology Platform. The Company seeks to accomplish this mission through a combination of internal development efforts and the efforts of the Company’s third-party licensees.
RGNX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$28.75
Change (%) Stock is Up 1.65 (6.09%)
Volume115,420
Data as of 02/22/18 1:30 p.m. ET
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: RGNX.O.  Currently trading at $28.75 with a 52 week high of $36.45 and a 52 week low of $16.30.
Recent NewsMore >>
DateTitle 
02/08/18REGENXBIO Announces Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD
Clinical trial evaluates one-time treatment for wet AMD using NAV® AAV8 gene therapy 18 patients have been dosed at leading retinal surgery centers in the United States Anticipate reporting topline data in late 2018 ROCKVILLE, Md., Feb. 08, 2018 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced it ha... 
Printer Friendly Version
02/07/18REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Feb. 07, 2018 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the following February investor conferences: SunTrust Robinson Humphrey 2018 Orphan Drug Day Date: Tuesday, February 13, 2018 Location: JW Marriott Essex House, New York, NY LEERINK Partners 7th Ann... 
Printer Friendly Version
01/23/18REGENXBIO Enhances Gene Therapy Manufacturing Capabilities by Entering into Strategic Partnership with FUJIFILM Diosynth Biotechnologies
- REGENXBIO has established internal capability to produce NAV AAV across multiple platforms and at scale of up to 200L - Agreement with FUJIFILM secures access to dedicated cGMP suite capacity and resources capable of manufacturing NAV AAV at up to 2,000L scale in support of global development and commercialization ROCKVILLE, Md., Jan. 23, 2018 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative poten... 
Printer Friendly Version
01/08/18REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy
AveXis acquires exclusive rights to entire NAV Technology Platform for the development of treatments for SMA Amended agreement permits assignment by AveXis upon a change of control without REGENXBIO’s consent REGENXBIO could receive up to $260 million, including $140 million in guaranteed upfront and annual payments              ROCKVILLE, Md. and CHICAGO, Jan. 08, 2018 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX) and AveXis, Inc. (Nasdaq:AVXS) today announced that they have enter... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Presentations
DateTitle
01/08/18
Corporate PresentationDownload Documentation 
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever REGENXBIO posts new information to the site. Just enter your e-mail address and click Submit.